# A Phase I/II Study of WJB001 Combination Therapy on Safety and Efficacy for Advanced Solid Tumors

> **NCT06953323** · PHASE1,PHASE2 · RECRUITING · sponsor: **Wigen Biomedicine Technology (Shanghai) Co., Ltd.** · enrollment: 86 (estimated)

## Conditions studied

- Advanced Solid Tumor

## Interventions

- **DRUG:** WJB001 Capsules+Paclitaxel/Paclitaxel-albumin
- **DRUG:** WJB001 Capsules+carboplatin/Nedaplatin
- **DRUG:** WJB001 Capsules+Paclitaxel+carboplatin
- **DRUG:** WJB001 Capsules+Niraparib
- **DRUG:** WJB001 Capsules+Bevacizumab
- **DRUG:** WJB001 Capsules+JS207/JS001
- **DRUG:** WJB001 Capsules+Paclitaxel+carboplatin+JS207/Toripalimab

## Key facts

- **NCT ID:** NCT06953323
- **Lead sponsor:** Wigen Biomedicine Technology (Shanghai) Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-07-10
- **Primary completion:** 2029-06-30
- **Final completion:** 2029-12-30
- **Target enrollment:** 86 (ESTIMATED)
- **Last updated:** 2026-03-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06953323

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06953323, "A Phase I/II Study of WJB001 Combination Therapy on Safety and Efficacy for Advanced Solid Tumors". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT06953323. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*